# Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

> **NCT03311659** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 448 (actual)

## Conditions studied

- Diphtheria-Tetanus-acellular Pertussis Vaccines

## Interventions

- **BIOLOGICAL:** Boostrix

## Key facts

- **NCT ID:** NCT03311659
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-08-31
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311659, "Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03311659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*